Elite Pharmaceuticals has begun dosing of a pilot bioequivalence study in healthy volunteers for ELI-201, the company’s twice daily abuse deterrent oxycodone/naltrexone product. A pivotal bioequivalence study for a second abuse deterrent product is scheduled to begin dosing in January 2014, and the pivotal bioequivalence study for ELI-201 is scheduled to begin dosing in March 2014. The bioequivalence studies for these opioid abuse deterrent products are being conducted under the direction...